VIA
IOVA icon

Vident Investment Advisory’s Iovance Biotherapeutics IOVA Stock Holding History

Vident Investment Advisory’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-112,238
Closed -$686K – 1261
2023
Q1 		$686K Sell
112,238
-3,288
-3% -$22.7K 0.02% 659
2022
Q4 		$738K Buy
115,526
+38,897
+51% +$304K 0.03% 576
2022
Q3 		$731K Sell
76,629
-8,010
-9% -$92.4K 0.02% 678
2022
Q2 		$934K Buy
84,639
+20,434
+32% +$268K 0.03% 642
2022
Q1 		$1.07M Buy
64,205
+10,540
+20% +$163K 0.03% 673
2021
Q4 		$1.02M Sell
53,665
-9,320
-15% -$205K 0.03% 698
2021
Q3 		$1.55M Sell
62,985
-4,500
-7% -$106K 0.05% 540
2021
Q2 		$1.76M Buy
67,485
+34,477
+104% +$896K 0.05% 462
2021
Q1 		$1.04M Hold
33,008
– – 0.04% 600
2020
Q4 		$1.53M Sell
33,008
-8,981
-21% -$357K 0.06% 395
2020
Q3 		$1.38M Sell
41,989
-6,087
-13% -$187K 0.07% 402
2020
Q2 		$1.32M Sell
48,076
-11,611
-19% -$382K 0.07% 381
2020
Q1 		$1.79M Sell
59,687
-1,736
-3% -$46K 0.12% 201
2019
Q4 		$1.7M Sell
61,423
-11,494
-16% -$261K 0.11% 298
2019
Q3 		$1.33M Sell
72,917
-2,083
-3% -$46.1K 0.12% 131
2019
Q2 		$1.84M Sell
75,000
-81,495
-52% -$1.23M 0.15% 96
2019
Q1 		$1.49M Sell
156,495
-5,162
-3% -$50.1K 0.08% 349
2018
Q4 		$1.43M Sell
161,657
-17,822
-10% -$172K 0.08% 333
2018
Q3 		$2.02M Sell
179,479
-12,940
-7% -$184K 0.08% 327
2018
Q2 		$2.46M Sell
192,419
-17,911
-9% -$262K 0.1% 280
2018
Q1 		$3.1M Buy
210,330
+57,136
+37% +$865K 0.13% 229
2017
Q4 		$1.23M Sell
153,194
-32,434
-17% -$260K 0.06% 347
2017
Q3 		$1.44M Hold
185,628
– – 0.08% 320
2017
Q2 		$1.36M Buy
185,628
+60,092
+48% +$382K 0.11% 287
2017
Q1 		$935K Buy
125,536
+20,920
+20% +$153K 0.09% 310
2016
Q4 		$727K Buy
104,616
+17,220
+20% +$118K 0.09% 310
2016
Q3 		$719K Buy
87,396
+1,689
+2% +$14.3K 0.1% 313
2016
Q2 		$694K Sell
85,707
-91,013
-52% -$572K 0.1% 319
2016
Q1 		$898K Buy
176,720
+84,567
+92% +$463K 0.06% 356
2015
Q4 		$711K Buy
+92,153
New +$639K 0.09% 346

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Vident Investment Advisory's IOVA Position: Q2 2023 in Review

Vident Investment Advisory sold out of Iovance Biotherapeutics (IOVA) in Q2 2023, closing a stake of 112,238 shares — an estimated $686K sold.

Vident Investment Advisory first reported a position in IOVA in Q4 2015 and held it in 30 quarters. The position peaked at $3.1M in Q1 2018. 219 funds tracked by Wall St. Rank hold IOVA as of Q2 2023.

  • Vident Investment Advisory reported no remaining Iovance Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 112,238 Iovance Biotherapeutics shares in Q2 2023, an estimated $686K.
  • Vident Investment Advisory first reported a position in Iovance Biotherapeutics in Q4 2015 and held it in 30 quarters.
  • Vident Investment Advisory's Iovance Biotherapeutics position peaked at $3.1M in Q1 2018.
  • 219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.